相关实验视频
Updated: Jun 23, 2026
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.8K
与多克索鲁比诱导心脏毒性相关基因的功能验证
Hananeh Fonoudi1,2, Mariam Jouni1,2, Romina B Cejas1,2
1Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
JACC. CardioOncology
|March 21, 2024
概括
在人类诱导的多能干细胞干细胞衍生的心肌细胞 (hiPSC-CMs) 中,与环素诱导的心脏毒性 (AIC) 相关的基因的功能验证揭示了26个基因,这些基因在淘汰时增加了心脏毒性. 相反,对吸收载体的淘汰显示出对多克索鲁素诱导的心脏毒性 (DIC) 的保护作用.
科学领域:
- 心血管研究研究心血管研究
- 遗传学和基因组学 在
- 干细胞生物学 干细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 超过180种基因变异在统计学上与因人环素诱导的心脏毒性 (AIC) 有关.
- 缺乏功能验证阻碍了这些遗传发现的临床翻译.
研究的目的:
- 用人类诱导的多能干细胞干细胞衍生的心肌细胞 (hiPSC-CMs) 来功能验证与AIC相关的基因.
- 确定用于减轻多克索鲁比诱导心脏毒性 (DIC) 的新型遗传标.
主要方法:
- 系统的文献搜索确定了80个与AIC相关的基因,以及另外3个感兴趣的基因.
- 38个在心脏组织和hiPSC-CMs中表达的基因被选择用于功能研究.
- 使用CRISPR/Cas9基因编辑来淘汰hiPSC-CMs中的38个基因中的每一个,以评估DIC表型.
主要成果:
- 26个基因的淘汰,包括排泄载体 (例如,ABCC10,ABCC2) 和已知的DIC基因 (例如,CBR1,RAC2),增加了hiPSC-CM对DIC的敏感性.
- 吸收载体的淘汰 (例如,SLC28A3,SLC22A17) 对DIC产生了保护作用.
- 特定基因 (例如,ATP2B1,HNMT) 的淘汰对体外DIC表型没有显著影响.
结论:
- 建立了一个用于功能验证DIC相关基因的平台.
- 调查结果提供了对DIC变体关联的见解,以及心脏保护药物开发的潜在目标.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...